NasdaqGS:TXGLife Sciences
10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative
10x Genomics (TXG) closed out FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM basic EPS loss of US$0.35. Over recent quarters, the company has seen revenue fluctuate between US$149.0 million and US$172.9 million, while quarterly basic EPS has moved between a loss of US$0.40 and a profit of US$0.28, highlighting an uneven path on the income line. For investors, the latest print keeps the focus on...